<DOC>
	<DOCNO>NCT02182505</DOCNO>
	<brief_summary>Study demonstrate least one two dos Berodual® ( 50 µg fenoterol hydrobromide + 20 µg ipratropium bromide 25 µg fenoterol hydrobromide + 10 µg ipratropium bromide , 1 puff t.i.d . ) administer via Respimat® device give bronchodilator response inferior obtain one dose Berodual® ( 50 µg fenoterol hydrobromide + 21 µg ipratropium bromide , 2 puff t.i.d . ) administer via MDI ( chlorofluorocarbon-metered dose inhaler ) Aerochamber® safety profile least good paediatric asthma patient treat four week .</brief_summary>
	<brief_title>Safety Efficacy Berodual® Inhaled Via Respimat® Compared MDI ( Metered Dose Inhaler ) Pediatric Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<criteria>Diagnosis bronchial asthma accord ATS ( American Thoracic Society ) criteria Male female child 6 15 year old Screening FEV1 : 6090 % predict normal . Predicted normal value base reference value Cotes Airway obstruction reversibility : FEV1 increase ≥ 12 % baseline 30 60 minute administration 2 puff Berodual® MDI use Aerochamber® Ability train proper use MDI Aerochamber® Respimat® Ability perform technically satisfactory pulmonary function test No hospital admission exacerbation stable dosage pulmonary medication last four week Parent ( ) /legal guardian able willing give write informed consent accordance Good Clinical Practice ( GCP ) local legislation . The child willing give oral consent Patients significant disease asthma , e.g . history clinically significant cardiovascular , renal , neurological , hepatic endocrine dysfunction ( e.g . hyperthyreosis ) . A clinically significant disease define disease opinion investigator may either put patient risk participation study may influence result study ability patient participate complete study Tuberculosis indication treatment History cancer within last five year Patients undergone thoracotomy Current psychiatric disorder History life threaten pulmonary obstruction , active bronchiectasis , lung fibrosis , AIDS ( acquire immunity deficiency syndrome ) cystic fibrosis Severe bronchial asthma frequent nocturnal asthma attack acute exacerbation induce recurrent bronchial infection several time per year An upper low respiratory tract infection four week prior screen visit ( = Visit 1 ) 2week runin period Patients know narrowangle glaucoma raise intraocular pressure Patients know intolerance hypersensitivity trial medication include excipients Patients use oral corticosteroid medication within last 4 week Patients use leukotriene receptor antagonists 5LO ( lipoxygenase ) inhibitor within last 4 week Betablocker medication Patients take investigational drug one month six halflives ( whichever great ) prior screen visit Previous participation runin phase study Presence psychosocial factor patient and/or relative , discretion investigator , assure compliance medication , procedure and/or protocol</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>